INmune Bio Inc. - INMB STOCK NEWS

INmune Bio, Inc. (NASDAQ: INMB) announced a registered direct offering of 1,818,182 shares at $22.00 per share, raising approximately $40 million. The offering, set to close on July 16, 2021, is facilitated by A.G.P./Alliance Global Partners. Proceeds will support working capital, corporate purposes, and advancement of product candidates, particularly the Phase 2 trial of XPro1595 for Alzheimer’s disease, expected to start by year-end 2021. This funding aims to fully support the Alzheimer’s Phase II program.

INmune Bio announces the initiation of its first patient treatment in a Phase 1 clinical trial of INKmune, targeting high-risk myelodysplastic syndrome (MDS). This trial will assess safety, tolerability, and clinical response in MDS patients, a serious condition with no known cure. INKmune aims to enhance the activity of dysfunctional natural killer (NK) cells in patients. Initial findings indicate promising potential for treating MDS and possibly solid tumors. The Phase 1 study will enroll nine patients under a 3x3 dose escalation protocol.

On June 14, 2021, INmune Bio (NASDAQ: INMB) announced a $15 million credit facility with Silicon Valley Bank to fund the buyout of an option held by Xencor, Inc. for $18.3 million. This move eliminates the potential dilution of approximately 2.1 million shares. INmune has made significant progress in developing XPro1595, a treatment for neuroinflammation in conditions like Alzheimer’s. The company is focused on launching Phase 2 trials for XPro1595 later this year, following positive data earlier this year regarding its Alzheimer's application.

INmune Bio (NASDAQ: INMB) has received USAN approval for the generic name Pegipanermin for its lead candidate XPro1595. CEO RJ Tesi stated that this milestone marks the transition from experimental to advanced development, with plans for Phase 2 trials targeting Alzheimer’s disease and Treatment Resistant Depression. The company previously reported positive Phase 1b data showing reduced biomarkers of neuroinflammation in Alzheimer's patients. Pegipanermin utilizes a unique TNF neutralization technology, differentiating it from existing therapies.

INmune Bio (NASDAQ: INMB) announced that CEO RJ Tesi will present at the Alzheimer Disease Panel on May 26, 2021. The event, hosted by M-Vest and presented by Maxim Group LLC, features a panel discussion on advancements in Alzheimer’s drug development, including recent findings about donanemab and the upcoming June 7 PDUFA action date for aducanumab. The panel will include insights from various healthcare experts and companies like Cassava Sciences (SAVA) and Vivoryon Therapeutics (VVY). Join the webinar at 11:00 AM ET for key discussions in the field.

INmune Bio reported its Q1 2021 financial results and provided key business updates. The company is progressing in its Phase I trial of XPro1595 for Alzheimer's disease, showing promising interim results that support a Phase II trial later this year. Additionally, they began screening for a Phase I trial of INKmune for high-risk myelodysplastic syndrome. Financially, INmune raised approximately $29 million through an ATM agreement, but recorded a net loss of $4.6 million for the quarter. The company has $45.3 million in cash with no debt.

INmune Bio (NASDAQ: INMB) will host a conference call on May 5, 2021, at 4:30 PM ET, to discuss its first-quarter results for the period ending March 31, 2021, and provide a corporate update. The call can be accessed by dialing 1-877-407-0784 (or 1-201-689-8560 for international callers). A transcript will be available shortly after the call, with a replay accessible until May 12, 2021.

INmune Bio focuses on developing treatments targeting the innate immune system for various diseases.

INmune Bio, Inc. (NASDAQ: INMB) announced a participation by CEO Raymond J. Tesi, MD, in a fireside chat at the B Riley Neuroscience Conference scheduled for April 28, 2021, at 1:00 PM ET. The company focuses on developing therapies that leverage the innate immune system to combat diseases, with product platforms addressing conditions such as COVID-19, cancer, Alzheimer’s, and NASH. The event will provide an opportunity for investors to engage in virtual one-on-one meetings with the company.

INmune Bio, Inc. (NASDAQ: INMB) announced that Professor Mark Lowdell, PhD, will present at two medical meetings: the Innate Killer Digital Summit and the Festival of Biologics USA. At the Innate Killer Summit, he will discuss new findings on INKmune™, an NK-cell priming immunotherapy, which enhances the ability of NK cells to target tumors, showing superior activity compared to traditional cytokine approaches. The second presentation at the World Immunotherapy Congress will focus on improving NK-tumor cell interactions. Both events are crucial for showcasing INmune Bio's advancements in cancer immunotherapy.